Birchview Capital LP Sells 25,000 Shares of Alphatec Holdings, Inc. $ATEC

Key Points

• Birchview Capital LP reduced its holdings in Alphatec Holdings by 43.1%, selling 25,000 shares to own a total of 33,000 shares valued at approximately $335,000.
• Several institutional investors increased their stakes in Alphatec, with Wealth Enhancement Advisory Services LLC raising its holdings by 301.0% and GAMMA Investing LLC by an astounding 38,433.3%.
• Alphatec Holdings is currently rated as a "Buy" by six research analysts, with a consensus price target averaging $18.50.

Birchview Capital LP trimmed its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 43.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,000 shares of the medical technology company's stock after selling 25,000 shares during the period. Birchview Capital LP's holdings in Alphatec were worth $335,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ATEC. Wealth Enhancement Advisory Services LLC grew its holdings in Alphatec by 301.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company's stock worth $608,000 after acquiring an additional 45,027 shares during the period. GAMMA Investing LLC grew its holdings in Alphatec by 38,433.3% during the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock worth $228,000 after acquiring an additional 2,306 shares during the period. SG Americas Securities LLC grew its holdings in Alphatec by 28.3% during the first quarter. SG Americas Securities LLC now owns 56,927 shares of the medical technology company's stock worth $577,000 after acquiring an additional 12,553 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of Alphatec by 13.4% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock valued at $133,000 after purchasing an additional 1,552 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Alphatec by 6.9% in the 1st quarter. Rhumbline Advisers now owns 148,749 shares of the medical technology company's stock valued at $1,508,000 after purchasing an additional 9,661 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Stock Down 0.9%

NASDAQ ATEC traded down $0.15 during trading on Friday, reaching $16.40. 1,427,181 shares of the company's stock were exchanged, compared to its average volume of 2,023,593. The firm has a market capitalization of $2.43 billion, a PE ratio of -14.51 and a beta of 1.02. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $16.70. The company's fifty day simple moving average is $13.38 and its 200-day simple moving average is $11.92.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.08. The business had revenue of $185.54 million during the quarter, compared to analyst estimates of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The firm's revenue was up 27.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.29) EPS. Alphatec has set its FY 2025 guidance at EPS. Sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Transactions at Alphatec

In other news, COO Scott Lish sold 6,323 shares of Alphatec stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $16.01, for a total transaction of $101,231.23. Following the completion of the sale, the chief operating officer directly owned 658,707 shares in the company, valued at $10,545,899.07. The trade was a 0.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of the firm's stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $14.91, for a total value of $269,751.72. Following the completion of the transaction, the general counsel directly owned 438,331 shares in the company, valued at $6,535,515.21. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 510,247 shares of company stock valued at $7,627,527 in the last quarter. Corporate insiders own 20.90% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 price target for the company in a research report on Monday, June 16th. Barclays reiterated an "overweight" rating and issued a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Wall Street Zen upgraded Alphatec from a "hold" rating to a "buy" rating in a research report on Sunday. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $18.50.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.